News
MIST
1.700
0.00%
0.000
Milestone Pharmaceuticals Inc <MIST.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Milestone Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview. The company is expected to show a fall in quarterly revenue when it reports results on May 9. LSEG's mean analyst estimate for the company is for a Loss of 26 cents per share.
Reuters · 2d ago
Weekly Report: what happened at MIST last week (0429-0503)?
Weekly Report · 3d ago
Weekly Report: what happened at MIST last week (0422-0426)?
Weekly Report · 04/29 09:02
Weekly Report: what happened at MIST last week (0415-0419)?
Weekly Report · 04/22 09:02
Milestone Pharmaceuticals To Present Data On Etripamil At The Preventative Cardiovascular Nursing Symposium
Milestone Pharmaceuticals Inc. Will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium on April 18-20th in Orlando, FL. The company is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.
Benzinga · 04/17 12:12
Weekly Report: what happened at MIST last week (0408-0412)?
Weekly Report · 04/15 09:02
Milestone’s Etripamil Shows Promise in Self-Managed PSVT Treatment
TipRanks · 04/09 16:38
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability To Self-Manage Recurring PSVT, Presented At The American College Of Cardiology Annual Meeting
Milestone Pharmaceuticals Inc. Announced new clinical data demonstrating real-world application of etripamil for conversion of recurrent paroxysmal supraventricular tachycardia. The drug is an investigational new drug for the acute treatment of PSVT. The study was presented at the American College of Cardiology Scientific Sessions.
Benzinga · 04/08 15:37
MILESTONE® PHARMACEUTICALS ANNOUNCES ETRIPAMIL DATA DEMONSTRATING PATIENTS’ ABILITY TO SELF-MANAGE RECURRING PSVT, PRESENTED AT THE AMERICAN COLLEGE OF CARDIOLOGY ANNUAL MEETING
Reuters · 04/08 15:36
Weekly Report: what happened at MIST last week (0401-0405)?
Weekly Report · 04/08 09:02
Milestone Pharmaceuticals To Present Data On Etripamil At The American College Of Cardiology And European Heart Rhythm Association Annual Conferences
Milestone Pharmaceuticals Inc. Will present data on etripamil at two upcoming cardiology conferences this month. The company will deliver oral and poster presentations at the American College of Cardiology annual meeting in Atlanta and the European Heart Rhythm Association in Berlin. Milestone is a biopharmaceutical company focused on the development of innovative cardiovascular medicines.
Benzinga · 04/01 12:02
Weekly Report: what happened at MIST last week (0325-0329)?
Weekly Report · 04/01 09:02
Milestone’s Etripamil Aims to Revolutionize PSVT Treatment
TipRanks · 03/28 15:37
Weekly Report: what happened at MIST last week (0318-0322)?
Weekly Report · 03/25 09:02
Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 03/22 18:17
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Benzinga · 03/22 18:07
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals (MIST) and Plus Therapeutics (PSTV) have been upgraded to Buy by 2 analysts today. The company's shares closed at $1.65 on Friday. The analysts are bullish on the Healthcare sector and the company's prospects. Plus TherAPEutics and Milestone PharmaceuticalS have a combined market value of $1 billion.
TipRanks · 03/22 16:40
Analysts’ Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Checkpoint Therapeutics (CKPT)
Milestone Pharmaceuticals and Checkpoint Therapeutics have 2 analysts bullish on the Healthcare sector. Milestone has a Buy rating from H.C. Wainwright and a $34.00 price target. Checkpoint has a Moderate Buy consensus rating from The Street.
TipRanks · 03/22 16:30
Milestone Pharmaceuticals’ Etripamil Nears Approval: A Strong Buy Recommendation
TipRanks · 03/21 22:25
Milestone Pharmaceuticals Advances Etripamil Development
TipRanks · 03/21 19:07
More
Webull provides a variety of real-time MIST stock news. You can receive the latest news about Milestone Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.